Bicara Therapeutics Inc. BCAX

Set alert

Price alert · BCAX

All alert types
9.22 USD +1.29 +16.27%

As of Nov 3, 1:11 PM ET

Bid
9.21 × 1
Ask
9.23 × 5
7.90 Day range 9.48
7.87 52-week range 30.99
YTD
-45.22%
1 year
-42.30%
Open
8.03
Prev close
7.93
Mkt cap
609.78M
Vol
881.77K
Avg vol
1.06M
EPS
-3.08
P/E
0.00
Div yield
0.00%
More statistics
Low
7.90
High
9.48
Forward P/E
-4.96
Beta
-0.69
Short ratio
16.85
Inst. own
102.47%
Dividend
0.00
Ex-div date
Earnings
Nov 9, 2026
50-d avg
20.82
200-d avg
21.33
1y target
35.67

5D chart

Chart tools
Interval

Signals (98)
NameTimeAgo
SMA: BullishNov 3, 11:45 AM1 hour ago
SMA: BearishNov 3, 11:40 AM1 hour ago
SMA: BullishNov 3, 11:35 AM1 hour ago
RSI: OverboughtNov 3, 11:35 AM1 hour ago
MACD: Sell SignalNov 3, 11:20 AM1 hour ago
RSI: OverboughtNov 3, 9:50 AM3 hours ago
RSI: OverboughtNov 3, 9:35 AM3 hours ago
SMA: BullishNov 3, 9:30 AM3 hours ago
SMA: BullishNov 3, 9:30 AM3 hours ago
MACD: Buy SignalNov 3, 9:30 AM3 hours ago
RSI: OversoldNov 2, 3:50 PM21 hours ago
MACD: Sell SignalNov 2, 3:35 PM21 hours ago
RSI: OversoldNov 2, 3:30 PM21 hours ago
SMA: BearishNov 2, 3:10 PM22 hours ago
MACD: Buy SignalNov 2, 2:40 PM22 hours ago
RSI: OversoldNov 2, 2:35 PM22 hours ago
RSI: OversoldNov 2, 2:15 PM22 hours ago
RSI: OversoldNov 2, 1:40 PM23 hours ago
MACD: Sell SignalNov 2, 1:30 PM23 hours ago
SMA: BearishNov 2, 1:15 PM23 hours ago

Newest 20 of 98.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 35.67 +286.8% upside
Target (low)
20.00
Target (mean)
35.67
Target (high)
45.00
Ratings (0m) 14 13 buy · 1 hold · 0 sell
  • Strong buy3
  • Buy10
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 14
  • 1 month ago 14
  • 2 months ago 16
  • 3 months ago 15

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

BCAX analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.82167-0.97 – -0.42-0.67-22.6%00.0%12
Next quarter-0.85417-0.97 – -0.47-0.68-25.6%00.0%12
Current year-3.39-3.68 – -2.65-2.52-34.4%00.0%12
Next year-3.52-4.73 – -1.86-3.39-4.0%00.0%11

Upgrades and downgrades

The latest rating changes

BCAX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 19, 2026BTIGReiteratedBuyBuy
Aug 19, 2026BMO CapitalInitiated—Outperform
Aug 12, 2026Goldman SachsMaintainedNeutralNeutral
Aug 12, 2026WedbushMaintainedOutperformOutperform
Aug 12, 2026Morgan StanleyMaintainedOverweightOverweight
Aug 12, 2026MizuhoMaintainedNeutralNeutral
Aug 12, 2026Wells FargoMaintainedEqual-WeightEqual-Weight
Aug 12, 2026BTIGMaintainedBuyBuy
May 12, 2026Goldman SachsMaintainedNeutralNeutral
May 12, 2026Morgan StanleyMaintainedOverweightOverweight
May 11, 2026GuggenheimInitiated—Buy
Mar 31, 2026Goldman SachsMaintainedNeutralNeutral
Mar 31, 2026WedbushReiteratedOutperformOutperform
Mar 31, 2026Wells FargoMaintainedEqual-WeightEqual-Weight
Mar 31, 2026CitizensReiteratedMarket OutperformMarket Outperform
Mar 31, 2026HC Wainwright & Co.MaintainedBuyBuy
Mar 25, 2026B of A SecuritiesInitiated—Buy
Jan 29, 2026CitizensInitiated—Market Outperform
Jan 13, 2026WedbushReiteratedOutperformOutperform
Jan 8, 2026BTIGInitiated—Buy
Dec 18, 2025MizuhoInitiated—Neutral
Nov 11, 2025Wells FargoMaintainedEqual-WeightEqual-Weight
Aug 22, 2025HC Wainwright & Co.MaintainedBuyBuy
Aug 19, 2025Piper SandlerInitiated—Overweight
May 23, 2025Wells FargoUpgradeUnderweightEqual-Weight
May 16, 2025HC Wainwright & Co.MaintainedBuyBuy
Apr 17, 2025Wells FargoInitiated—Underweight
Apr 7, 2025HC Wainwright & Co.MaintainedBuyBuy
Mar 13, 2025Cantor FitzgeraldReiteratedOverweightOverweight
Feb 12, 2025WedbushReiteratedOutperformOutperform